# 1st Gen Model Zoetis Inc. Pharmaceutical preparations

Subscribe >> Deal exit on
July 21, 2017
Deal entry on
July 21, 2017
0.22%Expected margin
80.00% successful of 35 deals
$63.16 Last close price
at 21-jul-2017

ZTS

Model's trade recommendations 3.14% Return for period

8.81% Annual return

$30.64B Market Cap

β 1.03  

ZTS

Model (following trade recommendations)

ZTS

Underlying stock

S&P 500

Index
Return for period 3.14%
0.61%
1.78%
52wk return 9.37%
25.67%
16.82%
52wk Range
47.25—63.51
2000.54—2399.63
Sortino ratio 1.33
Sharpe ratio 0.96
Norm. RMSE 0.16%
Downside risk 6.42%
Volatility 8.82%
  • 0.42 (0.67%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Zoetis Inc. (ZTS) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for ZTS model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 489M
P/E 31.06
Shares Outstanding 491M
% Held by Insiders 0.31%
% Held by Institutions 95.10%
EPS (last reported FY) $1.96
EPS (last reported Q) $0.53
EPS, estimated (last reported Q) $0.48
Total revenues $5 B
Net income $1 B